Use of Hepatitis B Virus DNA Quantitation To Predict Hepatitis B e Antigen Reversion in Cases of Chronic Hepatitis B

Abstract
Seventy-three chronic hepatitis B patients who had either hepatitis B e antigen (HBeAg) seroconversion (group I) or HBeAg-negative disease (group II) were studied. HBV DNA levels at HBeAg seroconversion (group I) and at initial visits (group II) were significantly lower among patients who were persistently negative for HBeAg than among those who underwent HBeAg reversion.